Cytosar-U, Cytarabine News

Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 Liposome Injection in leukemia were presented at the 14th Congress of the European Hematology Association in Berlin, Germany, June 4-7, 2009 .

Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.

Clavis Pharma ASA presented results from its elacytarabine Phase I combination study in patients with acute myeloid leukaemia at the American Association of Cancer Research 100th Annual Meeting 2009 in Denver, USA.

Celator Pharmaceuticals today announced that new data from animal studies of CPX-351 Liposome Injection in consolidation treatment for leukemia and of CPX-1 Liposome Injection in combination with biological agents for the treatment of colorectal cancer were presented at the 100th Annual Meeting of the American Association for Cancer Research in ...

The molecular changes in vivo in acute myeloid leukemia cells early after start of conventional genotoxic chemotherapy are incompletely understood, and it is not known if early molecular modulations reflect ...

Elderly Patients with Mantle Cell Lymphoma - Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment.

The Leukemia & Lymphoma Society and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 Liposome Injection for treatment of ...

Abstract BACKGROUND: Survival of patients with primary central nervous system lymphoma has improved with methotrexate-based combination regimens and radiotherapy .

Seattle Genetics, Inc. announced today that an Independent Data Monitoring Committee has completed a pre-specified safety review of data from the ongoing phase IIb trial of lintuzumab in combination with ...

Celator Pharmaceuticals today announced that a Phase 1 dose escalating study of CPX-351 Liposome Injection established the recommended dose for Phase 2 studies and confirmed preliminary observations of safety, ...

LONDON and CAMBRIDGE, MA, and SAN FRANCISCO, CA, Dec 09, 2008 -- Cancer drug developer Antisoma plc announces that new data showing durable responses in patients treated with its novel chemotherapy drug AS1413 ...

LONDON and CAMBRIDGE, MA and SAN FRANCISCO, CA, Dec 08, 2008 -- Study reported at ASH is first randomised trial of an aptamer in cancer A webcast and conference call about the ASH presentations on AS1411 and ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology Comtex SAN FRANCISCO, Dec 07, ...